NYSE:OPK
Opko Health Inc Stock News
$1.25
-0.0500 (-3.85%)
At Close: May 08, 2024
OPKO Health to Report Third Quarter 2023 Financial Results on November 6, 2023
08:00am, Tuesday, 31'st Oct 2023
MIAMI, Oct. 31, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and nine months ended September 30, 2023 after the close of the U
OPKO Health to Present New Clinical Data on Rayaldee (ER Calcifediol) at Kidney Week 2023
04:25pm, Wednesday, 25'th Oct 2023
MIAMI, Oct. 25, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) will present late-breaking clinical data on RAYALDEE® extended-release calcifediol (ERC) at the American Society of Nephrology
OPKO Health (OPK) Gets BARDA Contract to Combat Antibody Threats
01:32pm, Friday, 06'th Oct 2023
OPKO Health's (OPK) latest awarded funding is likely to enable the development of novel multispecific antibodies against viral infectious disease threats.
OPKO Health (OPK) Ties Up for Oral Peptide Tablet Formulations
03:02pm, Wednesday, 13'th Sep 2023
OPKO Health's (OPK) latest Research Collaboration Agreement is likely to enable it to expand its pipeline to develop orally administered tablet presentations of long-acting peptides.
Reasons to Retain OPKO Health (OPK) Stock in Your Portfolio
01:32pm, Monday, 28'th Aug 2023
OPKO Health's (OPK) potential in RAYALDEE raises optimism about the stock.
OPKO Health (OPK) Q2 Earnings and Revenues Top Estimates
02:23pm, Monday, 07'th Aug 2023
Despite OPKO Health's (OPK) robust RAYALDEE sales and strength in the Pharmaceuticals segment, its overall second-quarter results reflect soft performances.
OPKO Health, Inc. (OPK) Q2 2023 Earnings Call Transcript
12:17am, Friday, 04'th Aug 2023
OPKO Health, Inc. (NASDAQ:OPK ) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Yvonne Briggs - LHA Investor Relations Phillip Frost - Chairman & Chief Executive Office
OPKO Health (OPK) Reports Q2 Loss, Tops Revenue Estimates
07:32pm, Thursday, 03'rd Aug 2023
OPKO Health (OPK) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to loss of $0.04 per share a year ago.
OPKO Health: Improving Profitability Should Drive Shares Forward Post Q2 Earnings
02:19pm, Monday, 31'st Jul 2023
OPKO Health stock has bounced back since February but remains down over 11% since last year. OPK stock's rally in recent months has been supported by strong buying volume and positive earnings revisio
OPKO Health to Report Second Quarter 2023 Financial Results on August 3, 2023
04:05pm, Tuesday, 25'th Jul 2023
MIAMI, July 25, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and six months ended June 30, 2023 after the close of the U.S. fi
New Strong Buy Stocks for July 19th
09:52am, Wednesday, 19'th Jul 2023
SOHO, FUTU, NEOG, OPK and THRX have been added to the Zacks Rank #1 (Strong Buy) List on July 19, 2023.
OPKO Health is the Little Giant of Diversified Healthcare
07:14am, Wednesday, 19'th Jul 2023
Diversified healthcare company OPKO Health Inc. NASDAQ: OPK shares may be low priced, but its businesses pipeline of treatments and upside potential may deserve a higher valuation. Shares trade at 1.6
Why Shares of Opko Health Jumped on Thursday
03:51pm, Thursday, 29'th Jun 2023
Opko will share profits on the drug's sales with Pfizer. Ngenla is a treatment for pediatric growth hormone deficiency.
OPKO Health's (OPK) NGENLA Approved by FDA for GHD Treatment
12:54pm, Thursday, 29'th Jun 2023
The latest approval for OPKO Health's (OPK) NGENLA is expected to reduce the treatment frequency from daily injections, thereby better serving the GHD patient pool.
Why Is OPKO Health (OPK) Down 17.2% Since Last Earnings Report?
12:39pm, Friday, 02'nd Jun 2023
OPKO Health (OPK) reported earnings 30 days ago. What's next for the stock?
